MedTrace Logo

A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder

NCT00253110 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2012-08-06

No results posted yet for this study

Summary

The purpose of the study is to compare the time to relapse in patients with schizophrenia and schizoaffective disorders receiving risperidone or haloperidol (antipsychotic medications) for at least 1 year.

Conditions

Interventions

DRUG

risperidone

DRUG

haloperidol

Sponsors & Collaborators

  • Janssen, LP

    lead INDUSTRY

Principal Investigators

  • Janssen, LP Clinical Trial · Janssen, LP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-05-31
Completion
1998-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00253110 on ClinicalTrials.gov